戻る Agenda
Case Study Sponsored by Agilent: Analytical Validation Approaches at Every Phase of Oligonucleotide Development
Session Chair(s)
Representative Invited
Switzerland
Analytical methods generate critical data that guide development decisions throughout the oligonucleotide lifecycle. However, applying commercial-stage validation expectations too early—or too late—can create inefficiencies and risk. This presentation explores a phase-appropriate analytical strategy that supports informed decision-making, successful technology transfer, and regulatory readiness. Attendees will gain practical guidance for aligning analytical activities with program goals from early development through commercialization.
Speaker(s)
Speaker
Mark Sanseverino
R&D Director, Agilent Technologies, Inc., United States